JP2002226383A - Skin care preparation having, long-acting antimicrobial spectrum of wide range - Google Patents

Skin care preparation having, long-acting antimicrobial spectrum of wide range

Info

Publication number
JP2002226383A
JP2002226383A JP2001021258A JP2001021258A JP2002226383A JP 2002226383 A JP2002226383 A JP 2002226383A JP 2001021258 A JP2001021258 A JP 2001021258A JP 2001021258 A JP2001021258 A JP 2001021258A JP 2002226383 A JP2002226383 A JP 2002226383A
Authority
JP
Japan
Prior art keywords
wide range
skin care
care preparation
microorganisms
long
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001021258A
Other languages
Japanese (ja)
Inventor
Masashi Fujii
政志 藤井
Takahiro Hayashi
隆博 林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP2001021258A priority Critical patent/JP2002226383A/en
Publication of JP2002226383A publication Critical patent/JP2002226383A/en
Pending legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

PROBLEM TO BE SOLVED: To solve the problem that a greater number of kinds of microorganisms are found in atopic dermatitis patients than those in normal healthy subjects and not a dew of them are changed into allergens, i.e., a wide range of microorganisms started from Staphylococcus aureus and fungi such as Candida albicans, Alternaria, Malassezia further to bacteria may be cited, consequently, thus a skin care preparation capable of nonspecifically eliminating the wide range of these microorganisms in order to treat eczematous dermatitises is needed. SOLUTION: This skin care preparation having a long-acting antimicrobial spectrum of wide range is characterized in that the long-acting skin care preparation comprises 0.1 wt.% to 10 wt.% of an antimicrobial sintered ceramic (antimicrobial silver ceramic, for short, containing silver, tricalcium phosphate, zinc oxide and silicon dioxide), 0.01-0.05 wt.% of hinokitiol (β-thujaplicin) and 0.01-0.5 wt.% of an essential oil (tea tree oil) of Melaleuca alternifolia leaf.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は、黄色ブドウ球菌や
カンジダ アルビカンスなどの湿疹型皮膚炎を悪化する
微生物を除去するための皮膚外用剤を提供する。
TECHNICAL FIELD The present invention provides an external preparation for skin for removing microorganisms such as Staphylococcus aureus and Candida albicans that exacerbate eczema dermatitis.

【0002】[0002]

【従来の技術】皮膚の微生物を除去する技術としては、
抗生物質やサルファ剤配合の外用剤が主であり、安息香
酸やその塩、チアントール、ビオゾール、木酢、竹酢等
の防腐殺菌剤を配合してなる外用剤があった。
2. Description of the Related Art Techniques for removing skin microorganisms include:
The main topic is an external preparation containing an antibiotic or a sulfa drug, and an external preparation containing an antiseptic disinfectant such as benzoic acid or a salt thereof, thianthol, biosol, wood vinegar or bamboo vinegar.

【0003】[0003]

【本発明が解決しようとする課題】報告によればアトピ
ー性皮膚炎患者からは、健常人に比較して多くの種類の
微生物が見つかっており、同時にアレルゲンに移行して
いる物も少なくない。 列記すると黄色ブドウ球菌をは
じめカンジダ アルビカンス、アルテルナリア、マラセ
チア ファファ等真菌からバクテリアまで多岐に渡って
いる。したがって、湿疹型皮膚炎を治療するためにはこ
れらの多岐に渡る微生物を全て除去出来る皮膚外用剤が
望まれている。最も有効な手段として抗生物質を配合し
た外用剤があったが、抗菌スペクトルが狭い事や、近年
それぞれの抗生物質に対する耐性菌の出現により、皮膚
の微生物に感染に関する状況は混迷を極めている。特に
メチシリン耐性黄色ブドウ球菌の出現は、湿疹型皮膚炎
を難治性にしている。また、安息香酸は0.1%の低濃
度でもヒスタミン遊離型の皮膚炎を惹起するとの問題が
あり、チアントールやビオゾール等は皮膚感作性の問題
もあり、ヒノキチオールやMelaleuca alt
ernifolia葉の精油も高濃度を塗布すると安全
性上の問題があった。また、皮膚に外用した後の持続性
が短いとの問題もあった。
According to reports, many types of microorganisms have been found in patients with atopic dermatitis as compared with healthy individuals, and many of them have been simultaneously transferred to allergens. The list is wide ranging from fungi to bacteria such as Staphylococcus aureus, Candida albicans, Alternaria, Malassezia fafa etc. Therefore, in order to treat eczema-type dermatitis, a skin external preparation that can remove all of these various microorganisms is desired. There has been an external preparation containing an antibiotic as the most effective means, but due to the narrow antibacterial spectrum and the emergence of resistant bacteria to each antibiotic in recent years, the situation concerning infection with skin microorganisms has become extremely confusing. In particular, the appearance of methicillin-resistant Staphylococcus aureus has made eczema dermatitis refractory. Also, benzoic acid has a problem of causing histamine-releasing dermatitis even at a low concentration of 0.1%, and thiantol and biosol have a problem of skin sensitization, and hinokitiol and Melaleuca alt.
Even if essential oil of ernifolia leaves is applied at a high concentration, there is a problem in safety. In addition, there is also a problem that the durability after external application to the skin is short.

【0004】[0004]

【問題を解決するための手段】持続性広範囲抗微生物ス
ペクトル皮膚外用剤
[Means for Solving the Problems] Sustained broad spectrum antimicrobial spectrum skin external preparation

【0005】本発明は、0.1重量%から10重量%の
抗菌性焼結セラミック(以下抗菌性銀セラミック:銀お
よびリン酸三カルシウム、酸化亜鉛、二酸化珪素を含
む)および0.01重量%から0.05重量%のヒノキ
チオール(β-ツヤプリシン)と0.01重量%から
0.5重量%のMelaleuca alternif
olia葉の精油(ティートォリーオイル)を配合する
ことを特徴とする持続性広範囲抗微生物スペクトル皮膚
外用剤であり、持続性広範囲抗微生物スペクトルの外用
剤の塗布により湿疹型皮膚炎の微生物汚染による皮膚を
治療する。その外用剤は、化粧品、医薬部外品または医
薬品の何れにも適用される。また、剤形としては、ゲル
状からクリーム状、パップ状、ローションなど各種の剤
形に応用される。その効果を補助するために基剤として
エタノールやグリセリン、1,3−ブチレングリコール
などの保湿剤や乾燥状態にする目的として亜鉛華やセル
ロース末などの各種粉体やジフェンヒドラミンやグリチ
ルリチン酸などの抗炎症剤およびサリチル酸等の殺菌剤
を併用する事もある。 また、アトピー性皮膚炎用とし
てチリダニ忌避性物質を配合することも有用である。
The present invention relates to an antibacterial sintered ceramic (hereinafter referred to as antibacterial silver ceramic: containing silver and tricalcium phosphate, zinc oxide and silicon dioxide) of from 0.1% to 10% by weight and 0.01% by weight. To 0.05% by weight of hinokitiol (β-thyaprisin) and 0.01% to 0.5% by weight of Melaleuca alternif
It is a persistent broad-spectrum antimicrobial spectrum skin external preparation characterized by blending essential oils of tea leaves (tea tory oil). Treat the skin. The external preparation is applied to any of cosmetics, quasi-drugs, and pharmaceuticals. The dosage form is applied to various dosage forms such as a gel form, a cream form, a cataplasm, a lotion and the like. In order to assist its effect, humectants such as ethanol, glycerin, and 1,3-butylene glycol are used as bases, and various powders such as zinc white and cellulose powder are used as drying agents, and anti-inflammatory substances such as diphenhydramine and glycyrrhizic acid are used. And a disinfectant such as salicylic acid may be used in combination. It is also useful to add a dust mite repellent substance for atopic dermatitis.

【0006】[0006]

【実施例】実施例1を示し本発明の詳細を記載する。実
施例1の処方を表1に記載する。実施例1は、使用直前
に振り混ぜて皮膚に塗布する。
EXAMPLE 1 Example 1 is described and details of the present invention are described. The formulation of Example 1 is described in Table 1. Example 1 is applied to the skin by shaking immediately before use.

【0007】[0007]

【表1】 [Table 1]

【0008】実施例1の抗微生物効果を最小阻止濃度で
調べた。用いた微生物の種類は7種で10の6乗から7
乗個の懸濁液に調整し定法により試験を実施した。 実
施例は、精製水にて段階希釈した分散液を用い、その他
被験物質も振りまぜながら試験を行った。 同時に実施
例は、太陽光に8時間暴露した試料も実施した。その結
果を、表2に示す。それぞれの被験物質単体の最小阻止
濃度に対し、実施例はさらに希釈した濃度においても阻
止を示した。実施例は、ク゛ラム陽性および陰性バクテリア
から真菌まで広範囲の抗菌スペクトルを示した。ヒノキ
チオールは、光に弱く、この試験においても太陽光8時
間の暴露後には効果が消失したが、実施例1は同条件下
においても、被験物質単体よりも低い濃度で有効であ
り、これら3種の混合による相乗作用と持続性が確認さ
れた。
The antimicrobial effect of Example 1 was examined at the minimum inhibitory concentration. Seven kinds of microorganisms were used, from 10 6 to 7
The test was carried out according to a standard method by adjusting the number of suspensions. In the examples, a test was carried out using a dispersion serially diluted with purified water while shaking other test substances. At the same time, the examples also carried out samples exposed to sunlight for 8 hours. Table 2 shows the results. The examples showed inhibition at even more diluted concentrations, relative to the minimum inhibitory concentration of each test substance alone. The examples showed a broad spectrum of antimicrobial activity from quorum positive and negative bacteria to fungi. Hinokitiol was weak to light and lost its effect after exposure to 8 hours of sunlight in this test, but Example 1 was effective at a lower concentration than the test substance alone under the same conditions. The synergistic effect and persistence of the mixture were confirmed.

【0009】[0009]

【表2】 [Table 2]

【0010】[0010]

【発明の効果】実施例1を用い、アトピー性皮膚炎や黄
色ブドウ球菌感染による皮膚炎(以下トビヒ)、疥癬患
者の総数57例を被験者として、臨床試験を実施した。
アトピー性皮膚炎例中38著効30例、有効3例、やや
有効4例、無効1例であった。他方トビヒにおいては1
2例中著効10例、有効1例、やや有効1例、無効なし
で有り、疥癬においても3例中著効1例、有効1例、や
や有効1例、無効なしで有った。さらに原因が不明の湿
疹型皮膚炎においても4例中著効1例、有効1例、やや
有効1例、無効なしで有った。全ての症例をやや有効以
上についてまとめると約98%に効果が認められ、副作
用や悪化した例はなかった。
Using Example 1, a clinical test was conducted on a total of 57 patients with atopic dermatitis or dermatitis due to Staphylococcus aureus infection (hereinafter referred to as Tobii) and scabies.
Among the atopic dermatitis cases, 38 were excellent in 30 cases, effective in 3 cases, slightly effective in 4 cases, and ineffective in 1 case. On the other hand, 1
Among 2 cases, 10 cases were excellent, 1 case was effective, 1 case was fairly effective, and there was no ineffectiveness. In 3 cases of scabies, 1 case was excellent, 1 case was effective, 1 case was somewhat effective, and there was no ineffectiveness. Further, in eczema-type dermatitis of unknown cause, 1 out of 4 cases was excellent, 1 was effective, 1 was slightly effective, and there was no invalid. When all the cases were summarized to be somewhat effective or more effective, about 98% showed an effect, and there were no side effects or worsened cases.

Claims (1)

【特許請求の範囲】[Claims] 【請求項1】0.1重量%から10重量%の抗菌性焼結
セラミック(以下抗菌性銀セラミック:銀およびリン酸
三カルシウム、酸化亜鉛、二酸化珪素を含む)および
0.01重量%から0.05重量%のヒノキチオール
(β-ツヤプリシン)と0.01重量%から0.5重量
%のMelaleuca alternifolia葉
の精油(ティートォリーオイル)を配合することを特徴
とする持続性広範囲抗微生物スペクトル皮膚外用剤。
1. An antibacterial sintered ceramic (hereinafter referred to as antibacterial silver ceramic containing silver and tricalcium phosphate, zinc oxide and silicon dioxide) of from 0.1% to 10% by weight and from 0.01% to 0% by weight. 0.15% by weight of hinokitiol (β-thyaprisin) and 0.01% to 0.5% by weight of essential oil of leaf of Melaleuca alternifolia (tea tree oil). External preparation.
JP2001021258A 2001-01-30 2001-01-30 Skin care preparation having, long-acting antimicrobial spectrum of wide range Pending JP2002226383A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2001021258A JP2002226383A (en) 2001-01-30 2001-01-30 Skin care preparation having, long-acting antimicrobial spectrum of wide range

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001021258A JP2002226383A (en) 2001-01-30 2001-01-30 Skin care preparation having, long-acting antimicrobial spectrum of wide range

Publications (1)

Publication Number Publication Date
JP2002226383A true JP2002226383A (en) 2002-08-14

Family

ID=18886850

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001021258A Pending JP2002226383A (en) 2001-01-30 2001-01-30 Skin care preparation having, long-acting antimicrobial spectrum of wide range

Country Status (1)

Country Link
JP (1) JP2002226383A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008031023A1 (en) 2008-06-30 2009-12-31 Neubourg Skin Care Gmbh & Co. Kg Foam skin care cream
EA013509B1 (en) * 2008-04-22 2010-06-30 Иностранное Частное Унитарное Производственно-Торговое Предприятие "Инкраслав" Фирмы "Вера, О.О.О. Прешов" Antiseptic composition for disinfection of cutaneous covering
EA014063B1 (en) * 2008-09-08 2010-08-30 Иностранное Частное Унитарное Производственно-Торговое Предприятие "Инкраслав" Фирмы "Вера, О.О.О. Прешов" Detergent composition for disinfection of cutaneous covering and method of preparing thereof
JP2017190322A (en) * 2016-04-08 2017-10-19 有限会社岡本屋 Staphylococcus aureus inhibiting solution, atopic dermatitis treating solution, method for using atopic dermatitis treating solution, cosmetics, cleaning solution and antiseptic solution
WO2022000038A1 (en) * 2020-06-30 2022-01-06 Advance NanoTek Ltd. Sanitizing, antimicrobial hand, face and body moisturiser

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA013509B1 (en) * 2008-04-22 2010-06-30 Иностранное Частное Унитарное Производственно-Торговое Предприятие "Инкраслав" Фирмы "Вера, О.О.О. Прешов" Antiseptic composition for disinfection of cutaneous covering
DE102008031023A1 (en) 2008-06-30 2009-12-31 Neubourg Skin Care Gmbh & Co. Kg Foam skin care cream
EA014063B1 (en) * 2008-09-08 2010-08-30 Иностранное Частное Унитарное Производственно-Торговое Предприятие "Инкраслав" Фирмы "Вера, О.О.О. Прешов" Detergent composition for disinfection of cutaneous covering and method of preparing thereof
JP2017190322A (en) * 2016-04-08 2017-10-19 有限会社岡本屋 Staphylococcus aureus inhibiting solution, atopic dermatitis treating solution, method for using atopic dermatitis treating solution, cosmetics, cleaning solution and antiseptic solution
WO2022000038A1 (en) * 2020-06-30 2022-01-06 Advance NanoTek Ltd. Sanitizing, antimicrobial hand, face and body moisturiser

Similar Documents

Publication Publication Date Title
DE60020342T2 (en) DEEP-PUNCHING ANTIMICROBIAL COMPOSITIONS
EP0700249B1 (en) Anti-infective agents
Rajabalian et al. Cytotoxicity evaluation of Persica mouthwash on cultured human and mouse cell lines in the presence and absence of fetal calf serum
RU2653488C2 (en) Wound local treatment composition
US20040131567A1 (en) Antibacterial topical formulations
US6555125B2 (en) Lesion and ulcer medication
Acar et al. Comparison of silver-coated dressing (Acticoat®), chlorhexidine acetate 0.5%(Bactigrass®) and nystatin for topical antifungal effect in Candida albicans-contaminated, full-skin-thickness rat burn wounds
KR20070092095A (en) Disinfecting composition and methods of making and using same
US6352711B1 (en) Lesion and ulcer medication
DE69917248T2 (en) TOPICAL ANTISEPTIC COMPOSITIONS AND METHOD
EP2170398B1 (en) Use of a synergistic composition as a therapeutic agent or disinfectant
JP2002226383A (en) Skin care preparation having, long-acting antimicrobial spectrum of wide range
DE102010013275A1 (en) Microbiologically stable, application-friendly W / O preparations
KR20170130714A (en) A Cleanser composition containing hypochlorous acid and wet tissue comprising in the same
JP4902929B2 (en) Industrial antibacterial composition and antibacterial method
NO328979B1 (en) Use of dichlorobenzyl alcohol for the preparation of a composition for topical treatment of inflammation
WO2017038872A1 (en) Composition having antifungal activity
US10376488B2 (en) Use of flavonoids in manufacturing compositions for wound healing
JP2005008591A5 (en)
AU723716B2 (en) Topical medicament comprising phenolic biocide and choline
KR102417303B1 (en) Composition for preventing or improving atopic dermatitis
JP2522719B2 (en) Topical preparation for treatment of pressure ulcer and skin ulcer
KR20210031466A (en) Enhancement of antibacterial activity of depsipeptide antibiotics using synergistic boric acid
DE202012000247U1 (en) Composition for topical application II
RU2805656C1 (en) Liquid balm and a method of its preparation